Drug Profile
LY 2503029
Alternative Names: LY2503029Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics
- Mechanism of Action Proto oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Metastatic disease) in USA (PO)
- 01 Dec 2015 LY 2503029 is available to patients with Solid tumours (Late-stage disease, Metastatic disease) under expanded access programme in USA (NCT02632994)
- 01 Dec 2011 Pharmacokinetics and adverse events data from a phase I trial in Solid tumours released by Eli Lilly